Related references
Note: Only part of the references are listed.Perspective Rational Cancer Treatment Combinations: An Urgent Clinical Need
Julia Boshuizen et al.
MOLECULAR CELL (2020)
Reversal of pre-existing NGFR-driven tumor and immune therapy resistance
Julia Boshuizen et al.
NATURE COMMUNICATIONS (2020)
Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy
Tuba N. Gide et al.
CANCER CELL (2019)
Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold
David W. Vredevoogd et al.
CELL (2019)
Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis
Max D. Wellenstein et al.
NATURE (2019)
An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer
Marian L. Burr et al.
CANCER CELL (2019)
AXL Targeting Overcomes Human Lung Cancer Cell Resistance to NK- and CTL-Mediated Cytotoxicity
Stephane Terry et al.
CANCER IMMUNOLOGY RESEARCH (2019)
TAM Family Receptor Kinase Inhibition Reverses MDSC-Mediated Suppression and Augments Anti-PD-1 Therapy in Melanoma
Alisha Holtzhausen et al.
CANCER IMMUNOLOGY RESEARCH (2019)
TCF-1-Centered Transcriptional Network Drives an Effector versus Exhausted CD8 T Cell-Fate Decision
Zeyu Chen et al.
IMMUNITY (2019)
AXL Is a Putative Tumor Suppressor and Dormancy Regulator in Prostate Cancer
Haley D. Axelrod et al.
MOLECULAR CANCER RESEARCH (2019)
Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer
Louise A. Koopman et al.
JCI INSIGHT (2019)
Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors
Julia Boshuizen et al.
NATURE MEDICINE (2018)
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan et al.
NATURE (2018)
Humanized Mice for the Study of Immuno-Oncology
Philippe De La Rochere et al.
TRENDS IN IMMUNOLOGY (2018)
XenofilteR: computational deconvolution of mouse and human reads in tumor xenograft sequence data
Roelof J. C. Kluin et al.
BMC BIOINFORMATICS (2018)
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
Frank Stephen Hodi et al.
LANCET ONCOLOGY (2018)
HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes
Rina M. Mbofung et al.
NATURE COMMUNICATIONS (2017)
Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution
Nicholas McGranahan et al.
CELL (2017)
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab
Nadeem Riaz et al.
CELL (2017)
Integrative Analysis Identifies a Novel AXL-PI3 Kinase-PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer
Heath D. Skinner et al.
CLINICAL CANCER RESEARCH (2017)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma et al.
CELL (2017)
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
Weiyi Peng et al.
CANCER DISCOVERY (2016)
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Willy Hugo et al.
CELL (2016)
Immunophenotyping of Stage III Melanoma Reveals Parameters Associated with Patient Prognosis
Nicolas Jacquelot et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
Itay Tirosh et al.
SCIENCE (2016)
Reprogramming the immunological microenvironment through radiation and targeting Axl
Todd A. Aguilera et al.
NATURE COMMUNICATIONS (2016)
Tumor Radiosensitization by Monomethyl Auristatin E: Mechanism of Action and Targeted Delivery
Lisa Buckell et al.
CANCER RESEARCH (2015)
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Stefani Spranger et al.
NATURE (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade
Philipp Mueller et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
HTSeq-a Python framework to work with high-throughput sequencing data
Simon Anders et al.
BIOINFORMATICS (2015)
The microtubule-depolymerizing agent ansamitocin P3 programs dendritic cells toward enhanced anti-tumor immunity
Kea Martin et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
CD137 Accurately Identifies and Enriches for Naturally Occurring Tumor-Reactive T Cells in Tumor
Qunrui Ye et al.
CLINICAL CANCER RESEARCH (2014)
Genetic Evolution of T-cell Resistance in the Course of Melanoma Progression
Antje Sucker et al.
CLINICAL CANCER RESEARCH (2014)
The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells
Magdalena Paolino et al.
NATURE (2014)
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma
Judith Mueller et al.
NATURE COMMUNICATIONS (2014)
A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors
David J. Konieczkowski et al.
CANCER DISCOVERY (2014)
Microtubule-Depolymerizing Agents Used in Antibody-Drug Conjugates Induce Antitumor Immunity by Stimulation of Dendritic Cells
Philipp Mueller et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Michael I. Love et al.
GENOME BIOLOGY (2014)
Immunogenic Cell Death in Cancer Therapy
Guido Kroemer et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 31 (2013)
Epidermal growth factor receptor R521K polymorphism shows favorable outcomes in KRAS wild-type colorectal cancer patients treated with cetuximab-based chemotherapy
Yao-Yu Hsieh et al.
CANCER SCIENCE (2012)
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Zhenfeng Zhang et al.
NATURE GENETICS (2012)
Functional and genomic profiling of effector CD8 T cell subsets with distinct memory fates
Surojit Sarkar et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
Selecting highly affine and well-expressed TCRs for gene therapy of melanoma
Annelies Jorritsma et al.
BLOOD (2007)
Macrophages and dendritic cells use different Axl/Mertk/Tyro3 receptors in clearance of apoptotic cells
Heather M. Seitz et al.
JOURNAL OF IMMUNOLOGY (2007)
Effector memory T cells, early metastasis, and survival in colorectal cancer
F Pagès et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells
L Gattinoni et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Share Paper
